Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn&apos;s Disease: A Three-Patient Case Series

Inflammatory Bowel Disease

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study

J Crohns Colitis

Loftus EV Jr, D'Haens G, Louis E, Regueiro M, Jairath V, Magro F, Nakase H, Dubcenco E, Lacerda AP, Ford S, Feng T, Duncan B, Fish I, Cunneen C, Anyanwu SI, Aponte F, Griffith J, Blumenstein I

doi: 10.1093/ecco-jcc/jjaf138

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Inflammatory Bowel Disease

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Clin Gastroenterol Hepatol

Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, Steinlauf A, Schwartz D, Feng T, Dubcenco E, Anyanwu SI, Laroux FS, Cunneen C, Powell N

doi: 10.1016/j.cgh.2024.08.032

Further Publications

Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study

Gut

Adler J, Gadepalli S, Rahman M, Kim S

doi: 10.1136/gutjnl-2024-333280

Inflammatory Bowel Disease

MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease

Insights Imaging

Sakai NS, Plumb AA, Ahmed N, Chowdhury K, Kilic Y, Hameed M, Patel A, Bhagwanani A, Helbren E, Hyland R, Bhatnagar G, Sidhu H, Lambie H, Franklin JM, Mohsin M, Thomson E, Boone D, Tolan D, Rahman S, Ding N, Moran GW, Bloom S, Hart A, Menys A, Travis S, Halligan S, Taylor SA, Motility trial investigators

doi: 10.1186/s13244-025-01930-w

Further Publications

Perianal Disease in Pediatric-Onset Crohn's Disease: Incidence, Disease Course, and Long-Term Outcomes

Clin Gastroenterol Hepatol

Ström A, Jansson S, Wewer MD, Burisch J, Malham M, Wewer V

doi: 10.1016/j.cgh.2025.05.015

Inflammatory Bowel Disease

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study

Am J Gastroenterol

Lee SD, Vermeire S, Ungaro R, Vadhariya A, Durand F, Morris N, Yu G, Fisher DA, Traxler K, Long M

doi: 10.14309/ajg.0000000000003410

Inflammatory Bowel Disease

Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on Infliximab

J Crohns Colitis

Magro F, Domingues B, Estevinho MM, Patita M, Arroja B, Lago P, Rosa I, de Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Fernandes S, Dias CC, Dias S, Peyrin-Biroulet L, Danese S, Santiago M, GEDII

doi: 10.1093/ecco-jcc/jjaf120

Inflammatory Bowel Disease

Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease

BMC Gastroenterol

Karki C, Hantsbarger G, Turkstra E, Fenu E, Genenz K, Gilaberte I, Panés J

doi: 10.1186/s12876-024-03513-3

Gastroenterology

Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series

Related content

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study

MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease

Perianal Disease in Pediatric-Onset Crohn's Disease: Incidence, Disease Course, and Long-Term Outcomes

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study

Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on Infliximab

Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease